Breaking Finance News

A statement released earlier today by Piper Jaffray about CoLucid Pharmaceuticals (NASDAQ:CLCD) bumps the target price to $49.00

Boasting a price of $38.35, CoLucid Pharmaceuticals (NASDAQ:CLCD) traded 9.90% higher on the day. With the last stock price close up 276.84% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. CoLucid Pharmaceuticals has recorded a 50-day average of $18.82 and a two hundred day average of $10.13. Volume of trade was up over the average, with 715,077 shares of CLCD changing hands over the typical 621,016

Piper Jaffray bumped up the target of CoLucid Pharmaceuticals (NASDAQ:CLCD) to $49.00 stating a potential upside of 0.28%.

On 9/19/2016, Stifel Nicolaus released a statement for CoLucid Pharmaceuticals (NASDAQ:CLCD) bumped up the target price from $27.00 to $30.00 that suggested an upside of 0.07%.

Performance Chart

CoLucid Pharmaceuticals (NASDAQ:CLCD)

With a total market value of $0, CoLucid Pharmaceuticals has with a one year low of $3.60 and a one year high of $39.05 .

Brief Synopsis About CoLucid Pharmaceuticals (NASDAQ:CLCD)

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *